Jubilant Pharmova
Jubilant Pharmova
HealthcareKey Fundamentals
SmallcapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has been maintaining a healthy dividend payout of 43.9%
- Company's working capital requirements have reduced from 28.6 days to 13.4 days
Weaknesses
3- The company has delivered a poor sales growth of 6.31% over past five years.
- Company has a low return on equity of 4.91% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 2d agoJubilant Pharmova Ltd trades at a market cap of ₹16,125 Cr with a PE of 46.5x and a dividend yield of 0.49%. The company shows improving TTM sales growth of 16% but TTM profit has declined 20%, while its 3-year ROE averages just 5%, reflecting a business in transition with mixed financial signals.
- TTM revenue growth has accelerated to 16%, significantly above the 5-year compounded sales CAGR of 6% and 10-year CAGR of 4%, indicating a recent uptick in business momentum
- 3-year compounded profit growth of 47% shows the company went through a strong earnings recovery cycle from a low base
- Working capital efficiency has improved materially, with working capital days declining from 28.6 days to 13.4 days, freeing up cash for operations and debt servicing
- The company maintains a healthy dividend payout ratio of 43.9%, signaling management confidence in cash flow sustainability and commitment to returning capital to shareholders
- 3-year stock CAGR of 33% reflects the market has recognized the turnaround trajectory over the medium term
- Price-to-book ratio of 2.3x is relatively moderate for a healthcare company with a ₹16,125 Cr market cap, suggesting the stock is not at extreme valuation levels on a book value basis
- 10-year stock CAGR of 8% demonstrates the company has generated positive long-term returns for shareholders through business cycles
- PE ratio of 46.5x is elevated, yet TTM profits have declined 20%, meaning the high multiple is not backed by current earnings momentum
- 5-year compounded profit CAGR is negative at -13%, indicating the company has structurally struggled to grow earnings over a meaningful period
- 3-year average ROE of just 5% and last year's ROE of 7% are well below the cost of equity for most investors, reflecting poor capital efficiency
- 5-year compounded sales growth of only 6.31% is sluggish for a mid-cap healthcare company operating in a sector that typically grows faster in India
- 10-year compounded profit CAGR of merely 1% shows the company has barely grown its bottom line over a full decade, raising questions about long-term earnings power
- The 1-year stock return of -9% indicates recent market sentiment has turned negative despite the broader market performing well
- Potential capitalization of interest costs could mean reported profits are overstated and true debt servicing burden is higher than it appears on the income statement
- 10-year ROE of 9% and declining to 5% over 3 years shows a deteriorating trend in return on equity, suggesting diminishing profitability of reinvested capital
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 2h ago- ₹105.5Cr GST demand, Roorkee Aug 28
Subsidiary received show cause notice from Roorkee GST authorities proposing ₹52.75Cr tax demand plus equal penalty for FY21-FY22. Company contests the notice citing legal errors.
- Q1FY27 PAT drops 45% Aug 23
Consolidated PAT fell 45.1% YoY to ₹56.4Cr in Q1FY27 despite 17.3% revenue growth. EBITDA margin narrowed sharply from 15.2% to 11.1% due to absence of high-margin SPECT products and Montreal remediation costs.
- Stock down 17% YTD in 2026 Aug 23
Shares have declined over 17% in 2026 and nearly 19% over the last 12 months, trading at ₹877 as of Aug 22.
- ₹87.31Cr GST notice, Mysore Sep 1
Jubilant Pharmova received a ₹87.31Cr GST demand notice from Mysore tax authorities pertaining to FY23. No details on grounds or company response disclosed.
- USFDA approves Spokane Line 3 Aug 23
USFDA approved commercial batch manufacturing on new isolator-based fill-and-finish Line 3 at Spokane facility, expanding sterile injectable and ophthalmic capacity in the US for the CDMO business.
- CDMO Sterile Injectables up 34% Aug 23
CDMO Sterile Injectables revenue rose 34% to ₹496Cr in Q1FY27. Spokane facility revenue jumped 43% to ₹494Cr with EBITDA up 49% to ₹117Cr.
- SPECT production restart imminent Aug 23
Commercial batch production of SPECT radiopharmaceuticals has started after successful media-fills, with batches expected in Q2FY27 and full product availability by H2FY27.
- FY26 revenue up 14% to ₹83B Aug 26
Shareholders at 48th AGM approved all resolutions including ₹5 dividend. FY26 revenue grew 14% to ₹83 billion with Q1FY27 revenue up 17% YoY.
- MD re-appointments approved 99%+ Aug 17
Shareholders approved re-appointment of Managing Director and Joint Managing Director via postal ballot with over 99% votes in favour, ensuring management continuity.
TL;DR: Jubilant Pharmova shows strong top-line momentum with 17% Q1FY27 revenue growth and a fast-growing CDMO sterile injectables segment (up 34%), bolstered by USFDA approval of a new Spokane manufacturing line. However, profitability is under significant pressure with PAT down 45% and margins contracting due to the absence of high-margin SPECT products and remediation costs, compounded by cumulative GST demands totaling ~₹193Cr. The SPECT radiopharmaceutical restart in H2FY27 and new Line 3 capacity are key catalysts that could restore margins, but near-term earnings headwinds and regulatory tax disputes warrant caution.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | 2,229 |
| Expenses | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 |
| Operating Profit | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 |
| OPM % | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% | 17% | 14% | 15% | 11% |
| Other Income | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 |
| Interest | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 |
| Depreciation | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 |
| PBT | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 |
| Tax % | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% |
| Net Profit | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 |
| EPS in Rs | 0.4 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.5 | 3.55 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,751 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 8,280 | 8,608 |
| Expenses | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 | 7,020 | 7,390 |
| Operating Profit | 610 | 1,256 | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,260 | 1,218 |
| OPM % | 11% | 22% | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% | 16% | 15% | 14% |
| Other Income | 86 | 4 | 19 | 36 | -249 | 225 | 263 | 8 | -9 | -76 | 416 | 7 | 15 |
| Interest | 368 | 371 | 341 | 284 | 220 | 200 | 184 | 145 | 188 | 272 | 240 | 212 | 217 |
| Depreciation | 288 | 347 | 291 | 415 | 371 | 340 | 349 | 382 | 554 | 382 | 369 | 440 | 470 |
| PBT | 40 | 542 | 738 | 859 | 904 | 1,233 | 1,133 | 630 | 28 | 170 | 981 | 614 | 546 |
| Tax % | 200% | 29% | 22% | 26% | 36% | 27% | 26% | 34% | 333% | 57% | 15% | 35% | — |
| Net Profit | -40 | 387 | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 398 | 351 |
| EPS in Rs | -3.63 | 24.6 | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 | 22.11 |
| Div. Payout % | -83% | 12% | 8% | 7% | 12% | 9% | 10% | 19% | -130% | 102% | 9% | 20% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 2,438 | 2,951 | 3,420 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 | 6,239 | 7,077 |
| Borrowings | 4,793 | 4,493 | 4,045 | 3,469 | 4,840 | 4,808 | 2,830 | 3,192 | 3,677 | 3,664 | 2,731 | 3,615 |
| Other Liabilities | 1,372 | 1,280 | 1,417 | 1,902 | 1,670 | 1,898 | 1,192 | 1,319 | 1,853 | 2,240 | 3,598 | 4,564 |
| Total Liabilities | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 15,272 |
| Fixed Assets | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 | 5,176 | 6,966 |
| CWIP | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 | 3,630 | 4,040 |
| Investments | 40 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 | 61 |
| Other Assets | 3,071 | 2,939 | 3,006 | 3,262 | 4,654 | 5,133 | 3,017 | 3,631 | 3,928 | 4,101 | 3,735 | 4,205 |
| Total Assets | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 15,272 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 783 | 1,099 | 1,268 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | 661 | 971 | 1,072 | 1,227 |
| Investing | -362 | -309 | -465 | -614 | -1,018 | -267 | -727 | -323 | -474 | -596 | 512 | -1,143 |
| Financing | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | -33 | -157 | -432 | -1,453 | 95 |
| Net Cash Flow | -82 | -52 | 117 | -212 | 761 | 225 | -652 | 482 | 30 | -58 | 132 | 179 |
| Free Cash Flow | 434 | 760 | 806 | 819 | 473 | 975 | 1,270 | 241 | -135 | 83 | -38 | -120 |
| CFO/OP | 141 | 91 | 104 | 103 | 84 | 116 | 155 | 90 | 111 | 131 | 112 | 114 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 60 | 63 | 55 | 51 | 79 | 49 | 55 | 56 | 50 | 45 | 47 |
| Inventory Days | 169 | 207 | 223 | 177 | 147 | 463 | 268 | 308 | 268 | 220 | 178 | 170 |
| Days Payable | 99 | 106 | 137 | 145 | 106 | 273 | 124 | 139 | 160 | 146 | 158 | 170 |
| Cash Conversion Cycle | 122 | 162 | 149 | 87 | 92 | 268 | 194 | 224 | 165 | 124 | 65 | 47 |
| Working Capital Days | 12 | 4 | 50 | 45 | 45 | 62 | 74 | 56 | 57 | 56 | 16 | 13 |
| ROCE % | 6% | 13% | 15% | 15% | 16% | 15% | 12% | 10% | 3% | 7% | 10% | 9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Jubilant Pharmova insights
70 extracted metrics + investor summaries across FY11–FY26.
Documents
Frequently Asked Questions about Jubilant Pharmova
What does Jubilant Pharmova Ltd do?
Where is Jubilant Pharmova Ltd (JUBLPHARMA) listed?
Which sector does Jubilant Pharmova Ltd belong to?
What is the market capitalisation of Jubilant Pharmova Ltd?
What is the PE ratio of Jubilant Pharmova Ltd?
What is the 52-week high and low of Jubilant Pharmova Ltd?
Does Jubilant Pharmova Ltd pay dividends?
What is the Return on Equity (ROE) of Jubilant Pharmova Ltd?
Company Information
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JUBLPHARMA.md for Jubilant Pharmova Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.